Eli Lilly remains a buy after Q2, with robust revenue growth and strong performance from Mounjaro and Zepbound. LLY raised 2026 revenue guidance to $85–87 billion, driven by volume gains despite price declines, and reinforced margin expansion. Retatrutide is a key medium-term catalyst, with a BLA submission planned for Q1 2027 and potential in new therapeutic areas.